Ultrastructure of giant cell tumors of bone.

G. Steiner,L. Ghosh,H. Dorfman

DOI: https://doi.org/10.1016/S0046-8177(72)80007-8

IF: 3.526

1972-12-01

Human Pathology

Abstract:

What problem does this paper attempt to address?

Imaging Features, Staging System, and Surgical Management of Giant Cell Lesions of the Temporal Bone.

Xiaohong Li,Yi Wen,Jie Zhang,Nan Wu,Weidong Shen,Shiming Yang,Pu Dai,Dongyi Han,Yang,Weiju Han,Bo Feng,Guojian Wang

DOI: https://doi.org/10.1080/00016489.2022.2099969

IF: 1.698

2022-01-01

Acta Oto-Laryngologica

Abstract:BACKGROUND:Giant cell tumors (GCTs) and giant cell granulomas (GCGs) are giant cell-rich lesions that occur extremely rarely in the temporal bone and have similar clinical presentations.OBJECTIVES:We aimed to analyze the clinical features and introduce our staging system and surgical treatment.METHODS:Forty-six patients pathologically diagnosed with a giant cell lesion involving the temporal bone between October 2001 and October 2020 were reviewed retrospectively. The clinical characteristics, surgical approaches, and risk factors for recurrence were analyzed.RESULTS:GCTs and GCGs presented as masses centered on the temporomandibular joint with similar imaging features, including a thin, calcified shell and central scattered calcifications on a computed tomography scan. Differences were detected on magnetic resonance imaging in 29.6% (4/14) of GCG and 50% (16/32) of GCT cases; the remaining cases were not distinguishable. Based on our staging system and surgical strategy, 31.8% (7/22) of GCT and 10% (1/10) of GCG cases experienced recurrence, which compares to recurrence rates of 60% in GCT cases and 20% in GCG cases in previous studies.CONCLUSIONS:Specific clinical and preoperative imaging features help to make a diagnosis of temporal giant cell-rich lesions. Our staging system and surgical strategy could help surgeons tailor the surgical strategy.
Giant cell tumor of bone revisited

Andreas F. Mavrogenis,Vasileios G. Igoumenou,Panayiotis D. Megaloikonomos,Georgios N. Panagopoulos,Panayiotis J. Papagelopoulos,Panayotis N. Soucacos

DOI: https://doi.org/10.1051/sicotj/2017041

2017-01-01

Abstract:Giant cell tumor (GCT) of bone is a locally aggressive benign neoplasm that is associated with a large biological spectrum ranging from latent benign to highly recurrent and occasionally metastatic malignant bone tumor. It accounts for 4-10% of all bone tumors and typically affects the meta-epiphyseal region of long bones of young adults. The most common site involved is the distal femur, followed by the distal radius, sacrum, and proximal humerus. Clinical symptoms are nonspecific and may include local pain, swelling, and limited range of motion of the adjacent joint. Radiographs and contrast-enhanced magnetic resonance imaging (MRI) are the imaging modalities of choice for diagnosis. Surgical treatment with curettage is the optimal treatment for local tumor control. A favorable clinical outcome is expected when the tumor is excised to tumor-free margins, however, for periarticular lesions this is usually accompanied with a suboptimal functional outcome. Local adjuvants have been used for improved curettage, in addition to systematic agents such as denosumab, bisphosphonates, or interferon alpha. This article aims to discuss the clinicopathological features, diagnosis, and treatments for GCT of bone.
The XIVth Internation Symposium on Laboratory Animals. Section I: Avian immunology. Conclusions.

M. Simonsen

Folia biologica

Abstract:
Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options

Corey Montgomery,Cory Couch,Richard Nicholas,Cynthia Emory

DOI: https://doi.org/10.1055/s-0038-1675815

2018-11-16

The Journal of Knee Surgery

Abstract:Abstract Giant cell tumor of bone is a benign albeit aggressive tumor commonly affecting the bones of the knee. Patients with these tumors present with pain, swelling, and inability to bear weight on the involved extremity. These destructive tumors typically arise in the metaphyseal region of the long bones in individuals in the second, third, and fourth generations of life. Histologically, the multinucleated giant cells are the hallmark of the lesion, easily recognized on histological review, which recently have become therapeutic targets for medical management of the disease. For decades, surgical management has been the primary treatment for giant cell tumor of the bone. Some tumors can be treated with excision and filling of the osseous void with bone cement or allograft. This is an effective treatment option with a low to moderate risk of local recurrence while preserving limb function. For more destructive tumors, wide excision and reconstruction with prosthetic, structural allograft or combined allograft prosthetic components are utilized. Advances in medical management of the disease have also demonstrated promise as an effective treatment; however, its use has usually been limited to the treatment of metastatic disease, recurrent disease or when advanced local disease would require surgical treatment felt to be overly morbid.
Abstract 1486: the Immune Atlas and Chemokine Profile of Giant Cell Tumor of Bone

Binghao Li,Zhan Wang,Zhaoming Ye

DOI: https://doi.org/10.1158/1538-7445.am2019-1486

IF: 11.2

2019-01-01

Cancer Research

Abstract:Abstract Background and purpose: Giant cell tumor of bone (GCTB) is a locally aggressive tumor with metastatic potential. Given that GCTBs are composed of three major cell populations and the bone-resorption activity is attributed to the multinucleated giant cells which are conjectured to be recruited by “real” tumor cells, it is still elusive that how and what are these immune cells recruited. The purpose of this study is to present the immune landscape of GCTB, as well as to find out responsible chemokines during immune cell recruiting. Experimental procedures: We collected fresh GCTB tissues from surgical excisions. To identify immune cell composition within the tumor microenvironment, we performed mass cytometry (CyTOF) and conventional multicolor cytometry. Some fresh osteosarcoma and chondrosarcoma samples were also used to compare the immune atlas. For chemokine profiling, chemokine arrays were utilized. Further analysis on potential association between chemokines and immune cells were conducted. Results: For last updated, 47 GCTB fresh samples were collected, of which 12 cases received CyTOF analysis and the rest 35 samples were analyzed by multicolor cytometry. All GCTB samples were analyzed by chemokine array In-depth interrogation of the immune landscapes showed that compared with osteosarcoma and chondrosarcoma, GCTBs had some unique immune cell subgroups. Some CD163+ CD206+ macrophage clusters which expressed various immune suppressive markers were significantly enriched in GCTBs, while CD4+ CD25+ Treg cells were fewer in GCTB. In addition, some macrophage-like mononuclear cells (CD14- CD68+ CD163- CD206+ HLA-DR+) were only seen in GCTBs.Chemokine array revealed that higher levels of CXCL12, CCL22, and CCL7 might be associated with moremacrophage-like mononuclear cells in GCTBs. Conclusion: GCTB have very different immune features from other malignant bone tumors. Multiple chemokines may play important roles in recruiting “functional” monocytes. Such in-depth understanding has important implications in appropriate therapeutics for GCTB. Bigger sample size will further help in studying the immune and chemokine features of GCTB. Note: This abstract was not presented at the meeting. Citation Format: Binghao Li, Zhan Wang, Zhaoming Ye. The immune atlas and chemokine profile of giant cell tumor of bone [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1486.
Giant Cell Tumor of Bone: An Update

Atrayee Basu Mallick,Sant P. Chawla

DOI: https://doi.org/10.1007/s11912-021-01047-5

2021-03-22

Current Oncology Reports

Abstract:To highlight the new developments in the management of advanced giant cell tumor of bone, a rare locally aggressive benign tumor, which was traditionally managed with surgery alone by either curettage and local adjuvant therapy, wide resection, or marginal excision. Here, we review the current role of systemic therapy for management of locally advanced or metastatic giant cell tumor of bone (GCTB).

oncology
Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis

Ramses G Forsyth,Tibor Krenács,Nicholas Athanasou,Pancras C W Hogendoorn

DOI: https://doi.org/10.3390/cancers13205119

2021-10-13

Abstract:Giant cell tumour of bone (GCTB) is a rare and intriguing primary bone neoplasm. Worrisome clinical features are its local destructive behaviour, its high tendency to recur after surgical therapy and its ability to create so-called benign lung metastases (lung 'plugs'). GCTB displays a complex and difficult-to-understand cell biological behaviour because of its heterogenous morphology. Recently, a driver mutation in histone H3.3 was found. This mutation is highly conserved in GCTB but can also be detected in glioblastoma. Denosumab was recently introduced as an extra option of medical treatment next to traditional surgical and in rare cases, radiotherapy. Despite these new insights, many 'old' questions about the key features of GCTB remain unanswered, such as the presence of telomeric associations (TAs), the reactivation of hTERT, and its slight genomic instability. This review summarises the recent relevant literature of histone H3.3 in relation to the GCTB-specific G34W mutation and pays specific attention to the G34W mutation in relation to the development of TAs, genomic instability, and the characteristic morphology of GCTB. As pieces of an etiogenetic puzzle, this review tries fitting all these molecular features and the unique H3.3 G34W mutation together in GCTB.
The CT Manifestations of Giant Cell Tumor of Bone

龚向阳,杨光钊,张德钧,李森华

DOI: https://doi.org/10.3969/j.issn.1002-1671.2001.12.006

2001-01-01

Abstract:Objective To analyse CT signs of giant cell tumor of bone.Methods CT appearances of 42 cases of giant cell tumor of bone were reviewed.All patients were pathological proven.Results (1)Two kinds of bone destruction were seen in all ases:expansive cystic destruction and osteolytic destruction.The anterior was predominantly.(2)Most of our patients haven't bone septations in their tumors (95.2%).(3)Bone crests were usually seen in our study(63.2%).(4)Complete or incomplete sclerotic borders existed in 44.7% of all cases.(5)The inner bone soft tissues were heterogeneously in most of the patients.Fluid-fluid level can be seen in 5 cases (11.9%).(6)The outer-bone soft tissue masses were demonstrated in the majority cases with discontinuous bone shell.Conclusion CT may deepen our understanding and add imaging signs about giant cell tumor of bone;Which can enhance our diagnostic and differential diagnostic capability.
Report of the Purdue Workshop on Grand Challenges in Computer Architecture for the Support of High Performance Computing

H. Siegel,S. Abraham,W. Bain,K. Batcher,T. Casavant,D. DeGroot,J. Dennis,David C. Douglas,T. Feng,J. Goodman,Alan Huang,H. Jordan,J. R. Jamp,Y. Patt,A. Smith

DOI: https://doi.org/10.1016/0743-7315(92)90033-J

1992-11-01

Abstract:
Comment regarding the stability of active ingredients in long-expired prescription medications.

Michael M. Madden,F. Etzler,T. Gant

DOI: https://doi.org/10.1001/jamainternmed.2013.409

2013-06-10

JAMA Internal Medicine

Abstract:
State of the Art and New Concepts in Giant Cell Tumor of Bone: Imaging Features and Tumor Characteristics

Anna Parmeggiani,Marco Miceli,Costantino Errani,Giancarlo Facchini

DOI: https://doi.org/10.3390/cancers13246298

2021-12-15

Cancers

Abstract:Giant cell tumor of bone (GCTB) is classified as an intermediate malignant tumor due to its locally aggressive behavior, burdened by high local recurrence rate. GCTB accounts for about 4–5% of all primary bone tumors and typically arises in the metaphysis and epiphyses of the long tubular bones. Mutation of gene H3F3A is at the basis of GCTB etiopathogenesis, and its immunohistochemical expression is a valuable method for practical diagnosis, even if new biomarkers have been identified for early diagnosis and for potential tumor recurrence prediction. In the era of computer-aided diagnosis, imaging plays a key role in the assessment of GCTB for surgical planning, patients’ prognosis prediction and post treatment evaluation. Cystic changes, penetrating irregular margins and adjacent soft tissue invasion on preoperative Magnetic Resonance Imaging (MRI) have been associated with a higher rate of local recurrence. Distance from the tumor edge to the articular surface and thickness of unaffected cortical bone around the tumor should be evaluated on Computed Tomography (CT) as related to local recurrence. Main features associated with local recurrence after curettage are bone resorption around the graft or cement, soft tissue mass formation and expansile destruction of bone. A denosumab positive response is represented by a peripherical well-defined osteosclerosis around the lesion and intralesional ossification. Radiomics has proved to offer a valuable contribution in aiding GCTB pre-operative diagnosis through clinical-radiomics models based on CT scans and multiparametric MR imaging, possibly guiding the choice of a patient-tailored treatment. Moreover, radiomics models based on texture analysis demonstrated to be a promising alternative solution for the assessment of GCTB response to denosumab both on conventional radiography and CT since the quantitative variation of some radiomics features after therapy has been correlated with tumor response, suggesting they might facilitate disease monitoring during post-denosumab surveillance.

oncology
Clinicopathologic Study of Giant Cell Angioblastoma

Rong-Jun Mao,Qi-Ming Li,Yue-Ming Guo,Wei-Qiang Li,Chang-Shu Fan,Xiong-Zeng Zhu

DOI: https://doi.org/10.3760/cma.j.issn.0529-5807.2010.11.009

2010-01-01

Abstract:OBJECTIVE:to study the clinicopathological features, imaging characteristics, immunophenotypes and differential diagnosis of giant cell angioblastoma (GCAB).METHODS:a case of GCAB in the left middle-upper tibia and fibula was studied by light microscopy, X-ray and CT imaging, immunohistochemistry.RESULTS:X-ray and CT imaging showed a clearer lesion in the left middle-upper tibia than in the ipsilateral fibula with enlarged ostealleosis and increased inhomogeneously medullary cavity density, irregular thickening of cortical bone, local cortical default at the inner edge, soft tissue swelling around the abnormal bone. Histologically, tumor tissue was located between the bone trabeculae by nodular, linear and plexiform aggregates of oval-to-spindle cells, large mononucleate cells and multinucleate giant cells with prominent nucleoli and abundant granular eosinophilic cytoplasm. Some aggregates had uncentain amount of discernible lumens, either empty or containing few erythrocytes. A concentric arrangement of oval-to-spindle Cells around small-caliber vascular structures together with collagen fiber contributed to a so-called 'onion-skin' arrangement. The background showed a loose mesenchymal stroma formed of some inconspicuous spindle-fibroblast-like cells, stellate-shape mesenchymal cells, a moderate mononuclear inflammatory cell infiltrate and scattered mast cells. Immunophenotype showed the tumor cells and giant cells strongly positive for vimentin. A good many oval-to-spindle cells stained markedly for CD31 and CD34, but weakly for FVIII, while the giant cells are highlighted instead by CD68, occasionally, very few giant cells showed positive focally for FVIII, a-SMA decorated notedly the cells surrounding the endothelium-like cells but weakly positive in some other tumor cells.CONCLUSION:GCAB is a rare, locally infiltrative but slow growing neoplastic angiogenesis with unique morphological characteristics during infancy, which may occur not only in the skin, mucosa, subcutis and deep soft tissue but also in the bone.
[Purification and Study of the Characteristics of the Multinucleated Giant Cells of the Giant Cell Tumor].

Bo Liu,Shifeng Yu,Shuzhen Pang

DOI: https://doi.org/10.3321/j.issn:1671-167x.2003.01.006

2003-01-01

Abstract:OBJECTIVE:To harvest high purified osteoclast-like giant cells from the giant cell tumor by using trypsin and EDTA(ethylenediamineteraacetic acid) digestion. And explore the role and the origin of the multinucleated giant cells of the giant cell tumor.METHODS:Multinucleated giant cells were isolated and cultured from 8 cases of giant cell tumor of the long bone. After 20 hours of culture, 0.5 g.L-1 trypsin/0.2 g.L-1 EDTA was applied to detach the mononuclear stromal cells. The isolated multinucleated giant cells were inoculated on dentine slice to observe bone resorption ability in vitro. Immunohistochemistry study with V-ATPase, CA II (carbonic anhydrate II), cathepsin K, MMP-9 (matrix metalloproteinase-9), CD68 and TRAP(tartrate-resistant acid phosphatase) staining were carried out in the purified multinucleated giant cells.RESULTS:We obtained 85% purified multinucleated giant cells by trypsin/EDTA digestion. Multinucleated giant cells formed resorption lacunae on dentine slice in vitro and positively stained for V-ATPase, CA II, cathepsin K and MMP-9. The TRAP staining was also positive.CONCLUSION:Using 0.5 g.L-1 trypsin/0.2 g.L-1 EDTA digestion can get high purified multinucleated giant cells from the giant cell tumor. The multinucleated giant cells match all the character of the osteoclast and may originate from the fusion of the mononuclear stromal cells of the lesion.
RELATIONSHIP BETWEEN MICRO VASCULAR STRUCTURE AND BIOLOGICAL CHARACTERISTICS OF GIANT CELL TUMOUR OF BONE

Y SHEN,FW SHI,Y CHEN,GQ YUAN,HC SUN

1994-01-01

Abstract:The vascular architecture of bone giant cell tumor was observed histologically with resin cast technique and scanning electron microscopy. Three types of capillaries were noted in the tumor tissue: extruding club-like capillary in the outer zone of the tumor; sinusoid capillary running disorderly in the intermediate zone; cecum capillary in the central zone. The pattern of vascular structure was believed to be correlated with tumor growth.
Stro-1(+) Stromal Cells Have Stem-Like Features In Giant Cell Tumor Of Bone

Jie Lan,Xiaoguang Liu,Wei Rong,Feng Wei,Liang Jiang,Haiyan Yu,Gengting Dang,Zhongjun Liu

DOI: https://doi.org/10.1002/jso.23151

2012-01-01

Journal of Surgical Oncology

Abstract:Background: Giant cell tumor of bone (GCTB) is an aggressive benign bone tumor with poor prognosis whose neoplastic component is stromal cells (SCs). Tumor stem-like cells (TSCs) have been demonstrated as precursors for tumor genesis and growth. The aim of this study is to identify TSCs in GCTB.Methods: Stro-1(+) and Stro-1(-) cells were isolated by fluorescence-activated cell sorting (FACS). Stem-like properties of both Stro-1(+) and Stro-1(-) subpopulations were assessed using MTT colorimetric assays, cell cycle analyses, sphere formation assays, and differentiation assays. Molecular profiles were analyzed by flow cytometry, immunofluorescence, and qRT-PCR.Results: The existence of rare Stro-1(+) cells was confirmed in vitro using FACS and in vivo by immunohistochemistry. These Stro-1(+) cells exhibited higher proliferative and cisplatin-resistant potentials than Stro-1(-) cells. In serum-free suspension cultures, Stro-1(+) SCs could form cell spheres and maintain self-renewal. Furthermore, Stro-1(+) SCs could differentiate into two mesenchymal lineage cells: osteoblasts and adipocytes. Cell surface markers CD44, CD117, and CD133 and stem cell-associated genes OCT3/4, NANOG, and ABCG2 were significantly higher in the Stro-1(+) subpopulation. Conclusions: This study demonstrates that Stro-1(+) SCs in GCTB possess stem-like biological and molecular phenotypes, indicating that they are the TSCs of GCTB. J. Surg. Oncol. 2012; 106:826836. (C) 2012 Wiley Periodicals, Inc.
Surgical Management of Giant Cell Tumors of Long Bones in Recent 10 Years

HU Bo,ZHOU Guang-xin,REN Ke,SHI Xin,WU Su-jia

DOI: https://doi.org/10.3969/j.issn.1008-8199.2013.07.013

2013-01-01

Abstract:Objective Giant cell tumor(GCT) of bone is a common bone tumor characterized by active growth,strong corrosion and fast destruction,for which there are a variety of treatment options.The purpose of this article is to evaluate the clinical results of different surgical treatments for GCT of long bones.Methods We retrospectively analyzed the clinical and follow-up data of 60 cases of GCT of long bones treated from January 2000 to November 2010.The patients,32 males and 28 females,ranged in age from 15 to 61 years(mean 35 years).According to Campanacci's staging system,6 cases were classified as gradeⅠ,31 as grade Ⅱ and 23 as grade Ⅲ.Seventeen of them were treated by thorough curettage,alcohol deactivation of the tumor and bone transplantation,and 43 by enbloc resection.Results The follow-up time was from 17 to 132 months(mean 68 months).The total rate of local recurrence was 11.7%(7 /60),17.6% in the group of curettage + bone transplantation,3.3% in the group of prosthesis replacement + tumor resection + allogeneic bone transplantation,and 40% in the group of distal radius tumor excision + fibula autografting for functional reconstruction.Conclusion Intralesional curettage with adjuvant therapies remains the first choice treatment for GCT of long bones.For extensive,biologically aggressive and / or recurrent tumors,enbloc resection is more effective,but needs to be strictly indicated.
Imaging Findings of Giant Cell Tumor of Tendon Sheath

Li Bin,Wang Chao,Zhang Minming

DOI: https://doi.org/10.3760/cma.j.issn.1005-1201.2015.06.013

2015-01-01

Abstract:Objective To explore the imaging features of giant cell tumor of tendon sheath(GCTTS) so as to improve the accuracy of imaging diagnosis. Methods Thirty?nine cases of GCTTS confirmed by pathological examination were retrospectively analyzed.Of the 39 cases, 32 were diffuse form and 7 were localized form.Seventeen patients underwent X?ray examination,18 had CT pain examination,37 had pain MR imaging and 17 had contrast?enhanced MR imaging.Results X?ray showed local soft tissue masswith slightly high density, and the adjacent bones were shown destruction or erosion tovarious degrees(10/17). No obvious calcification and periosteal reaction were shown.CT scans could provide images better than X?ray films.CT showed local soft tissue masses in the peri?articular muscle gaps. Some tumors were lobulated with cross?jointed growth(8/18),and the adjacent bones were shown destruction or erosion tovarious degrees(11/18).No obvious calcification and periosteal reaction were shown. On MRI,most cases were isointense on T1WI(32/37),and hyperintense on T2WI(27/37). Most cases tended to be heterogeneously enhanced following Gd?DTPA administration(14/17).The lesions were typically located adjacent to a tendon or partially/completely encasing it. Conclusions The imaging findings of GCTTS have some certain characteristics. MRI is able to depict the characteristic internal signal of GCTT and its relationship with adjacent tissues, which is valuable for diagnosis, treatment and follow?up.
Serglycin Induces Osteoclastogenesis and Promotes Tumor Growth in Giant Cell Tumor of Bone.

Yunfei He,Dongdong Cheng,Cheng Lian,Yingjie Liu,Wenqian Luo,Yuan Wang,Chengxin Ma,Qiuyao Wu,Pu Tian,Dasa He,Zhenchang Jia,Xianzhe Lv,Xue Zhang,Zhen Pan,Jinxi Lu,Yansen Xiao,Peiyuan Zhang,Yajun Liang,Qingcheng Yang,Guohong Hu

DOI: https://doi.org/10.1038/s41419-021-04161-1

2021-01-01

Cell Death and Disease

Abstract:Giant cell tumor of bone (GCTB) is an aggressive osteolytic bone tumor characterized by the within-tumor presence of osteoclast-like multinucleated giant cells (MGCs), which are induced by the neoplastic stromal cells and lead to extensive bone destruction. However, the underlying mechanism of the pathological process of osteoclastogenesis in GCTB is poorly understood. Here we show that the proteoglycan Serglycin (SRGN) secreted by neoplastic stromal cells plays a crucial role in the formation of MGCs and tumorigenesis in GCTB. Upregulated SRGN expression and secretion are observed in GCTB tumor cells and patients. Stromal-derived SRGN promotes osteoclast differentiation from monocytes. SRGN knockdown in stromal cells inhibits tumor growth and bone destruction in a patient-derived orthotopic xenograft model of mice. Mechanistically SRGN interacts with CD44 on the cell surface of monocytes and thus activates focal adhesion kinase (FAK), leading to osteoclast differentiation. Importantly, blocking CD44 with a neutralizing antibody reduces the number of MGCs and suppresses tumorigenesis in vivo. Overall, our data reveal a mechanism of MGC induction in GCTB and support CD44-targeting approaches for GCTB treatment.
Nature of multinucleated giant cells in giant cell tumor and giant cell granuloma of the jaws

田雪飞,李铁军,于世凤

DOI: https://doi.org/10.3969/j.issn.1003-7632.2003.05.004

2003-01-01

Abstract:Objective To investigate the possible nature of the multinucleated giant cells (MGCs) in giant cell tumor (GCT) and giant cell granuloma (GCG) of the jaws.Methods Eight cases of GCT and 8 cases of GCG [4 central cases (CGCG) and 4 peripheral cases (PGCG)],1 case of scrofula and 1 case of foreign body giant cell granuloma were undergone immunohistochemical staining to detect CD68, AAT,AACT,lysozyme,MAC-387,vimentin,S-100 and Ki-67 using formalin-paraffin embedded tissue sections.Enzyme histochemical staining for tartrate-resistant acid phosphatase (TRAP),an enzyme marker for osteoclasts,was also performed in all cases.Results MGCs in GCT and GCG lesions possessed both histiocyte/monocyte related antigens (CD68,AAT,AACT) as well as osteoclast specific enzyme (TRAP).Ki67 staining,however,showed that only mononuclear cells,but not the MGCs,were in cell cycle.Conclusion The MGCs in GCT and GCG appeared to express both macrophage and osteoclast associated phenotypes.The exclusively proliferative activity demonstrated in the mononuclear cells and the similar immunocytochemical and histochemical expression in some of the mononuclear elements suggest that these cells may represent precursors of the MGCs.Coalescence or fusion of these precursor cells could result in giant cell formation in the lesion.
Giant Cell Tumors of the Skull: a Series of 18 Cases and Review of the Literature

Zhenyu Zhang,Jian Xu,Yu Yao,Shuguang Chu,Haixia Cheng,Danqi Chen,Ping Zhong

DOI: https://doi.org/10.1007/s11060-013-1242-z

2013-01-01

Journal of Neuro-Oncology

Abstract:Giant cell tumors (GCTs) are generally benign, locally aggressive lesions mostly located in the metaphysis of long bones. GCTs of the skull are rare and the majority of the cases have been presented as case reports. The authors retrospectively reported 18 patients with GCTs of the skull at a single institution from April 1994 to February 2012 and summarized the clinical, radiological, pathological characteristics and management of the disease. Meanwhile, a systematic review of 94 case reports of GCTs of the skull was performed. Headache and symptoms related to the involvement of intracranial nerves were the most common symptoms. Over 90 % of the tumors originated from sphenoid and temporal bones. On MRI, very low signal on T2-weighted images were found highly indicative of GCTs of the temporal bone. Univariate analysis revealed that extent of tumor resection and post-operative radiation therapy (RT) were prognostic factors significantly influencing the survival of the patients. We concluded that complete tumor resection is the optimal goal in treating this disease and adjuvant RT should be given once tumor residual is inevitable.

Ultrastructure of giant cell tumors of bone.

Imaging Features, Staging System, and Surgical Management of Giant Cell Lesions of the Temporal Bone.

Giant cell tumor of bone revisited

The XIVth Internation Symposium on Laboratory Animals. Section I: Avian immunology. Conclusions.

Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options

Abstract 1486: the Immune Atlas and Chemokine Profile of Giant Cell Tumor of Bone

Giant Cell Tumor of Bone: An Update

Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis

The CT Manifestations of Giant Cell Tumor of Bone

Report of the Purdue Workshop on Grand Challenges in Computer Architecture for the Support of High Performance Computing

Comment regarding the stability of active ingredients in long-expired prescription medications.

State of the Art and New Concepts in Giant Cell Tumor of Bone: Imaging Features and Tumor Characteristics

Clinicopathologic Study of Giant Cell Angioblastoma

[Purification and Study of the Characteristics of the Multinucleated Giant Cells of the Giant Cell Tumor].

RELATIONSHIP BETWEEN MICRO VASCULAR STRUCTURE AND BIOLOGICAL CHARACTERISTICS OF GIANT CELL TUMOUR OF BONE

Stro-1(+) Stromal Cells Have Stem-Like Features In Giant Cell Tumor Of Bone

Surgical Management of Giant Cell Tumors of Long Bones in Recent 10 Years

Imaging Findings of Giant Cell Tumor of Tendon Sheath

Serglycin Induces Osteoclastogenesis and Promotes Tumor Growth in Giant Cell Tumor of Bone.

Nature of multinucleated giant cells in giant cell tumor and giant cell granuloma of the jaws

Giant Cell Tumors of the Skull: a Series of 18 Cases and Review of the Literature